Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Andrea Matucci, Francesca Nencini, Emanuele Vivarelli, Susanna Bormioli, Enrico Maggi & Alessandra Vultaggio. (2021) Immunogenicity-unwanted immune responses to biological drugs – can we predict them?. Expert Review of Clinical Pharmacology 14:1, pages 47-53.
Read now
Read now
Lise Pedersen, Pal Bela Szecsi, Per Birger Johansen & Poul Jannik Bjerrum. (2020) Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study. Biologics: Targets and Therapy 14, pages 115-125.
Read now
Read now
Keiko Funahashi, Satoru Koyano, Hirotoshi Echizen & Tsukasa Matsubara. (2017) Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis. Modern Rheumatology 27:2, pages 271-277.
Read now
Read now
Benjamín Reyes-Beltrán & Gabriela Delgado. (2017) Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar – Preliminary report. Journal of Immunotoxicology 14:1, pages 103-108.
Read now
Read now
Mauro Keiserman, Catalin Codreanu, Rohini Handa, Daniel Xibillé-Friedmann, Eduardo Mysler, Francisco Briceño & Servet Akar. (2014) The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Review of Clinical Immunology 10:8, pages 1049-1057.
Read now
Read now
Articles from other publishers (15)
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad & Silje Watterdal Syversen. (2022) Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine. BioDrugs 36:6, pages 731-748.
Crossref
Crossref
Kai Huang, Nannan Chu, Ying Ding, Linglin Que, Zhenzhong Qian, Yunfei Shi, Wei Qin & Qing He. (2022) Comparative Pharmacokinetics, Safety, and Immunogenicity Study of the Prefilled Syringe and Lyophilized Formulation of a Recombinant Human Tumor Necrosis Factor‐α Receptor II:lgG Fc Fusion Protein in Healthy Chinese Male Subjects. Clinical Pharmacology in Drug Development 11:9, pages 1116-1123.
Crossref
Crossref
Ashvini Reddy, Fauziyya Muhammad & Darren J. Lee. 2019. Advances in the Diagnosis and Management of Uveitis. Advances in the Diagnosis and Management of Uveitis.
Matthew R. Gardner, Ina Fetzer, Lisa M. Kattenhorn, Meredith E. Davis-Gardner, Amber S. Zhou, Barnett Alfant, Jesse A. Weber, Hema R. Kondur, Jose M. Martinez-Navio, Sebastian P. Fuchs, Ronald C. Desrosiers, Guangping Gao, Jeffrey D. Lifson & Michael Farzan. (2019) Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. Molecular Therapy 27:3, pages 650-660.
Crossref
Crossref
Meghna Jani, William G Dixon & Hector Chinoy. (2018) Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology 57:11, pages 1896-1907.
Crossref
Crossref
B Gorovits, D J Baltrukonis, I Bhattacharya, M A Birchler, D Finco, D Sikkema, M S Vincent, S Lula, L Marshall & T P Hickling. (2018) Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clinical and Experimental Immunology 192:3, pages 348-365.
Crossref
Crossref
Evan A. Dubiel, Tamás Fülöp, Sylvain Vigier & Patrick Vermette. (2017) Quartz crystal microbalance as an assay to detect anti-drug antibodies for the immunogenicity assessment of therapeutic biologics. Analytical and Bioanalytical Chemistry 409:30, pages 7153-7167.
Crossref
Crossref
Oliver Richter, Andrej Skerjanec, Miguel Afonso, Sabine Sanguino Heinrich, Johann Poetzl, Heike Woehling, Maria Velinova, Annelize Koch, Dmitrij Kollins, Lars Macke & Guido Wuerth. (2016) GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. British Journal of Clinical Pharmacology 83:4, pages 732-741.
Crossref
Crossref
Paul Emery, Ji?? Vencovsk?Jeehoon Ghil & Jung Won Kang. (2016)
Response to: ?Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration? by Marshall
et al
. Annals of the Rheumatic Diseases 75:7, pages e38-e38.
Crossref
Crossref
Lisa Marshall, Timothy Hickling, David Bill & Ehab Mahgoub. (2016) Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration. Annals of the Rheumatic Diseases 75:7, pages e37-e37.
Crossref
Crossref
James Oliver, Darren Plant, Amy P Webster & Anne Barton. (2015) Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomarkers in Medicine 9:6, pages 499-512.
Crossref
Crossref
Meghna Jani, Hector Chinoy, Richard B. Warren, Christopher E. M. Griffiths, Darren Plant, Bo Fu, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, KimmeL. Hyrich, Anne Barton, P. J. Prouse, R. K. Moitra, D. J. Shawe, M. Nisar, K. Fairburn, J. Nixon, T. Barnes, M. Hui, D. Coady, D. Wright, C. Morley, G. Raftery, C. Bracewell, M. Bridges, D. Armstrong, A. J. Chuck, S. Hailwood, N. Kumar, D. Ashok, R. Reece, S. C. O'Reilly, T. Ding, L. J. Badcock, C. M. Deighton, N. Raj, M. R. Regan, G. D. Summers, R. A. Williams, J. R. Lambert, R. Stevens, C. Wilkinson, C. A. Kelly, J. Hamilton, C. R. Heycock, V. Saravanan, A. Cope, T. Garrood, N. Ng, B. Kirkham, M. Green, A. Gough, C. Lawson, D. Das, E. Borbas, T. Wazir, P. Emery, S. Bingham, H. A. Bird, P.G. Conaghan, C. T. Pease, R. J. Wakefield, M. Buch, I. Bruce, R. Gorodkin, P. Ho, B. Parker, W. Smith, E. Jenkins, C. Mukhtyar, K. Gaffney, A. J. Macgregor, T. Marshall, P. Merry, C. DeSilva, F. N. Birrell, P. R. Crook, B. Szebenyi, D. Bates, D. James, T. Gillott, A. Alvi, C. Grey, J. Browning, J. F. McHale, I.C. Gaywood, A. C. Jones, P. Lanyon, I. Pande, M. Doherty, A. Gupta, P. A. Courtney, A. Srikanth, A. Abhishek, L. Das, M. Pattrick, H. N. Snowden, A. P. Bowden, E. E. Smith, P. Klimiuk, D. J. Speden, S. Naz, J. M. Ledingham, R. G. Hull, F. McCrae, A. Cooper, S. A. Young‐Min, E. Wong, R. Shaban, A. D. Woolf, M. Davis, D. Hutchinson, A. Endean, D. Mewar, E. J. Tunn, K. Nelson, T. D. Kennedy, C. Dubois, J. Pauling, E. Korendowych, T. Jenkinson, R. Sengupta, A. Bhalla, N. McHugh, T. O'Neil, A. L. Herrick, A. K. Jones, R. G. Cooper, W. G. Dixon, B. Harrison, C. D. Buckley, D. C. Carruthers, R. Elamanchi, P. C. Gordon, K. A. Grindulis, F. Khattak, K. Raza, K. Situnayake, M. Akil, S. Till, L. Dunkley, R. Tattersall, R. Kilding, T. Tait, J. Maxwell, S. Till, K.-P. Kuet, M. J. Plant, F. Clarke, J. N. Fordham, S. Tuck, S. K. Pathare, A. Paul, C. P. Marguerie, S. P. Rigby, N. Dunn, I. Abbas, C. Filer, V. E. Abernethy, A. R. Clewes, J. K. Dawson, G. Kitas, N. Erb, R. Klocke, A. J. Whallett, K. Douglas, A. Pace, R. Sandhu, H. John, L. Shand, S. Lane, H. Foster, B. Griffiths, I. Griffiths, L. Kay, W.-F. Ng, P. N. Platt, D. J. Walker, P. Peterson, A. Lorenzi, M. Friswell, B. Thompson, M. Lee, A. Pratt, N. D. Hopkinson, C. A. Dunne, B. Quilty, J. Marks, S. Mukherjee, D. Mulherin, S. V. Chalam, T. Price, T. Sheeran, S. Venkatachalam, S. Baskar, W. Al- Allaf, F. McKenna, P. Shah, A. Filer, S. J. Bowman, P. Jobanputra, E. C. Rankin, M. Allen, K. Chaudhuri, S. Dubey, A. Price‐Forbes, J. Ravindran, A. Samanta, P. Sheldon, W. Hassan, J. Francis, A. Kinder, R. Neame, A. Moorthy, M. Bukhari, L. Ottewell, E. Palkonyai, S. Hider, A. Hassell, A. Menon, C. Dowson, S. Kamath, J. Packham, S. Dutta, S. Price, E. Roddy, Z. Paskins, D. T. O'Reilly, V. Rajagopal, S. Bhagat, C. B. Chattopadhyay, M. Green, D. Quinn, A. Isdale, A. Brown, B. Saleem, B. Foo, Z. Al Saffar & G. Koduri. (2015) Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis. Arthritis & Rheumatology 67:8, pages 2011-2019.
Crossref
Crossref
Der-Yuan Chen, Yi-Ming Chen, Wen-Chan Tsai, Jui-Cheng Tseng, Yi-Hsing Chen, Chia-Wei Hsieh, Wei-Ting Hung & Joung-Liang Lan. (2015) Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 74:3, pages e16-e16.
Crossref
Crossref
Marcello Govoni, Alessandra Bortoluzzi, Andrea Lo Monaco, Silvano Adami, Olga Addimanda, Cristian Caimmi, Salvatore De Vita, Clodoveo Ferri, Andreina Manfredi, Giovanni Orsolini, Niccolò Possemato, Luca Quartuccio, Carlo Salvarani, Alen Zabotti & Maurizio Rossini. (2014) Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritides. Advances in Therapy 31:8, pages 780-802.
Crossref
Crossref
Diana Mazilu, Daniela Opriş, Cecilia Gainaru, Mihaela Iliuta, Natalia Apetrei, Giorgiana Luca, Andreea Borangiu, Tania Gudu, Alexandra Peltea, Laura Groseanu, Cosmin Constantinescu, Ioana Saulescu, Violeta Bojinca, Andra Balanescu, Denisa Predeteanu & Ruxandra Ionescu. (2014) Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment. BioMed Research International 2014, pages 1-8.
Crossref
Crossref